Mission
Bringing beauty to the world.
Services
Developing and delivering the matsuri AI model
Our proprietary AI model, matsuri, is designed as a fully sovereign AI. Unlike commercial cloud AI services, it is designed to let users harness AI’s full capabilities without provider-imposed output restrictions. Guided by our aim to create AI that connects people’s hearts, we are building a range of AI-driven businesses around matsuri.
Brand Design
Our mission is to bring beauty to the world: to connect genuinely valuable ideas and things that move people with those who need them. We support the entire process, from strategy and creative production to media placement and performance evaluation, across television, newspapers, the web, social media, outdoor advertising, events and public relations. We are committed to expressing the value that matters in its most beautiful form.
CEO
Shoya Nagata
Born in 1996 in Anjo, Aichi, Japan. A graduate of the School of Engineering and Graduate School of Engineering at Nagoya University, now in his eighth year of AI research.
He began developing AI at age 22 and researched medical AI in graduate school. He participated in joint research with Takeda Pharmaceutical and Mitsubishi Kyoto Hospital and published a first-author paper in the peer-reviewed Journal of Pharmacological and Toxicological Methods. He is also named as a co-inventor on an international patent application for an arrhythmia severity classification device.
He decided to start a business in the second year of his master’s program and established IDEAL Japan in 2022. After beginning with web advertising, he now focuses on brand design and AI development.
Combining the analytical skills of a researcher with the execution skills of an entrepreneur, he turns technology into meaningful change for people and businesses.
His guiding principle is “Bringing beauty to the world.”
The patent application has been internationally published; this does not mean that a patent has been granted.
Research
Predicting drug-induced convulsions with machine learning
This study combines heart rate variability analysis and machine learning to detect early signs of drug-induced convulsions in cynomolgus monkeys. Shoya Nagata is the first author of the paper, published in the peer-reviewed Journal of Pharmacological and Toxicological Methods.
Paper title
Prediction of GABA receptor antagonist-induced convulsion in cynomolgus monkeys by combining machine learning and heart rate variability analysis
Journal
Journal of Pharmacological and Toxicological Methods, Volume 112, 2021
Intellectual Property
Arrhythmia Severity Classification Device
An invention relating to technology that classifies the severity of arrhythmia using biological information. Shoya Nagata is a co-inventor on the international patent application.
View the international publication
Inventors
藤原 幸一 / Shoya Nagata
International application number
PCT/JP2023/012844
International publication number
WO2023/218788
This is an internationally published patent application, not a statement that a patent has been granted.
Offices
Sapporo Office
1-7, Kita 32-jo Higashi 17-chome, Higashi-ku, Sapporo, Hokkaido 065-0032, Japan
Tokyo Office
1-20-13 Takanawa, Minato-ku, Tokyo 108-0074, Japan